Findings

What do systematic reviews say?

16 questions · 16 findings · 10 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 37.5%GRADE not reported 2 · 12.5%Very low 4 · 25%Low 0 · 0%Moderate 0 · 0%High 4 · 25%

Intravenous iron vs placebo

Overall quality of life measured at the end of · non‐anaemic, iron‐deficient adults

1 finding from 1 review

Intravenous iron therapy for non‐anaemic, iron‐deficient adults 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 344 participants
Very low

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Quality of life Â · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Intravenous iron vs oral iron

QoL · people with preoperative anaemia awaiting major surgery

The review found no eligible studies for this question.

1 finding from 1 review

Iron therapy for preoperative anaemia 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intravenous soya oil‐derived (n‐6) fatty acid‐based lipid emulsion vs intravenous fish oil‐derived (n‐3) fatty acid‐based lipid emulsion

Improvement in participant satisfaction measures and quality of life assessment measures Overall subjective score on 5 items (appearance of lesions, impairment of daily life, pruritus, burning, and pain) reported through figures · guttate psoriasis

1 finding from 1 review

Non‐antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 21 participants
Very low

Intravenous thyrotropin releasing hormone vs placebo

Change in quality of life · children with SMA types II and III

The review found no eligible studies for this question.

1 finding from 1 review

Drug treatment for spinal muscular atrophy types II and III 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1164 participants
High

Reslizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1652 participants
High

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (ACQ) Scale from: 0 to 6 (lower is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Mepolizumab intravenous (IV) vs placebo

Health‐related quality of life (AQLQ)Scale from: 1‐7 (higher is better) · people with asthma

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 369 participants
High

Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo

Health‐related quality of life · anemia in patients with rheumatoid arthritis

1 finding from 1 review

Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 136 participants
Very low

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Quality of life · adults and children with cystic fibrosis

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
GRADE not reported

Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy

Quality of life Â · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral antibiotics vs IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Single vs combination IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Nebulised antibiotics vs IV antibiotics

Quality of life · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

The review found no eligible studies for this question.

1 finding from 1 review

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rituximab vs intravenous methylprednisolone

Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Very low